Trimerbody Pharma

Molecular engineering for health

Immuno-oncology | Bispecific antibody | Immunostimulation | Tumour

Description

Trimerbody Pharma is a biopharmaceutical company dedicated to the development of multivalent and multispecific therapeutic antibodies, called Trimerbodies. Its antibodies are the result of internal R&D and collaborations with leading research centres and prominent companies in the sector.

The company has multiple development programmes in various therapeutic areas, including immuno-oncology, a high-growth field for both companies and investors.

At Trimerbody Pharma, they develop next-generation antibodies for cutting-edge therapies against advanced cancers, with the aim of offering hope to future patients affected by cancers for which current treatments are insufficient.

Trimerbody® is a registered trademark and is covered by international patents.

Featured projects

Milestone #1: In vitro validation of clinical candidate LEAD-452 and specific tumour localisation

Studies have shown that following intravenous administration, LEAD-452 demonstrates exceptional localisation in tumour tissue. Unlike competing IgG antibodies, ex vivo imaging confirmed that LEAD-452 localises exclusively in tumours, with no accumulation in vital organs such as the liver, spleen, kidneys, heart, or lungs.
Milestone #2: Preclinical efficacy with complete tumour remission

Preclinical trials with LEAD-452 showed complete tumour regression in 100% of mice bearing a colorectal adenocarcinoma xenograft. A high level of CD8+ T cell infiltration was also observed in the treated tumours, reinforcing its immunomodulatory potential.
Milestone #3: Specific memory immune response

Animals previously treated with LEAD-452 demonstrated resistance to re-challenge with colorectal tumour cells. This finding confirms LEAD-452’s capacity to induce a protective and long-lasting memory immune response.
Milestone #4: Scalable production and manufacturing process under GMP-like conditions

Using standard procedures, LEAD-452 was produced in CHO cells under GMP-like conditions, achieving yields of up to 2 g/L.
Milestone #5: Toxicity studies in non-human primates

In GLP-like toxicity studies, LEAD-452 was administered intravenously in both single and repeated doses. It was well tolerated up to the maximum administered dose of 20 mg/kg, with no evidence of hepatic or haematological toxicity, cytokine release syndrome, skin reactivity, or immunogenicity.